Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS Pre-Tax Margin
Income before tax as a percentage of revenue.
Keros Therapeutics, Inc.NASDAQ: KROS
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin narrows to -6459.9%
Pre-tax margin was -6459.9% in Q1 FY2026, down 6535.0 pp from a year earlier. On a trailing-twelve-month basis it was -272.2%, down 278.9 pp year over year.
Context
- Pre-tax margin widened in 2 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 37.7%
- Year-over-year change
- +5306.8pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.7% | +5306.8pp |
| FY2024 | 2024-12-31 | -5269.1% | +96050.1pp |
| FY2023 | 2023-12-31 | -101319.2% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | -282.3% | — |
Pre-Tax Margin vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 pre-tax margin of -272.2% is the 4th highest of the 7 companies compared; the peer median is -248.0%.
- Its year-over-year change of -278.9 pp is the 6th highest of 7, against a peer median of -96.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 40.7% | +21.9 pp | +90.1 pp | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | 15.1% | +1.6 pp | +37.0 pp |
| LTM Mar 2026 | -165.7% | -194.1 pp | +164.3 pp | |
| LTM Mar 2026 | -272.2% | -278.9 pp | — | |
| LTM Mar 2026 | -330.2% | -229.6 pp | +135.0 pp | |
| LTM Mar 2026 | -391.2% | +1095.8 pp | +2165.7 pp | |
| LTM Mar 2026 | -6445.8% | -4214.8 pp | -2277.8 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding KROS) | -248.0% | -96.2 pp | +112.6 pp | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.1M | 0 | 151K | 3.55M | 244.06M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.51M |
| Gross Profit | 20.1M | 0 | 151K | 3.55M | 242.55M |
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 99.4% |
| Research & Development | 55.14M | 87.27M | 135.26M | 173.63M | 129.64M |
| Selling, General & Admin | 21.33M | 27.53M | 34.83M | 40.75M | 46.85M |
| Operating Expenses | 76.47M | 114.79M | 170.09M | 214.38M | 171.93M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| EBITDA | (56.35M) | (104M) | (152.18M) | (185.82M) | 93.41M |
| EBITDA Margin | -280.4% | — | -100779.5% | -5234.5% | 38.3% |
| Operating Income | (56.37M) | (114.79M) | (169.94M) | (210.83M) | 70.62M |
| Operating Margin | -280.5% | — | -112543.7% | -5939.0% | 28.9% |
| Interest Income | 0 | 1K | 0 | 0 | 0 |
| Interest Expense | 4K | 1K | 0 | 0 | 0 |
| Other Income / Expenses | (360K) | 10.11M | 16.95M | 23.78M | 21.27M |
| Income Before Tax | (56.73M) | (104.68M) | (152.99M) | (187.05M) | 91.9M |
| Pre-Tax Margin | -282.3% | — | -101319.2% | -5269.1% | 37.7% |
| Income Tax Expense | 2.01M | 0 | 0 | 300K | 4.88M |
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Net Margin | -292.3% | — | -101319.2% | -5277.5% | 35.7% |
| EPS (Basic) | (2.52) | (4.15) | (5.20) | (5.00) | 2.34 |
| EPS (Diluted) | (2.52) | (4.15) | (5.20) | (5.00) | 2.30 |
| Weighted Avg Shares | 23.33M | 25.24M | 29.45M | 37.44M | 37.22M |
| Weighted Avg Shares (Diluted) | 23.33M | 25.24M | 29.45M | 37.44M | 37.86M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.